TNFRSF9 and neoplasm: The increase in inflammatory status, combined with the release of tumor-associated antigens induced by the treatment, implies the activation of CD137+ T cells, particularly CD4+CD137+ T cells, which secrete the pro-inflammatory cytokine interleukin 4 (IL-4).